CPI_Logo

New project to enhance nanomedicine development
0.0/5 rating (0 votes)

Thursday, 10 May 2018

The Centre for Process Innovation (CPI),based here at NETPark, has launched a new collaborative project that strengthens its nanoformulation capabilities to better develop next-generation nanomedicines. The project aims to evaluate a new microfluidic-based platform for the scale-up, process development and manufacture of nanoformulated medicines. If successful, CPI will make the new microfluidic-based platform available on an open-access basis at its National Formulation Centre. This will aid the development of new products and technologies emerging from academia and the biotech sector for clinical evaluation and commercialisation.

Nanoformulations can enhance conventional drug properties, such as improving intracellular delivery and tissue targeting. Ensuring that the right amount of a molecule can be delivered to the right tissue at the right time can enhance health outcomes and reduce negative side effects. Nanoformulations can therefore provide medicines and vaccines that are more effective, and enable new therapies for difficult-to-target sites, such as the delivery of nucleic acid therapies for cancer treatment.

The market for nanoformulated medicines is growing at a significant rate, with an estimated market value of $15.8 billion in 2014 and forecasted growth to $44.5 billion by 2019.[1] However, the development of robust and scalable processes for nanomedicines manufacture remains a challenge, with poor manufacturability being a potential barrier to commercial success for the next generation of nanoformulated medicines. The outcomes of the project have the potential to confer significant benefits for future medicines development, whilst further strengthening the North East of England’s position as a hub for medicines manufacture.

As part of this project, CPI will collaborate closely with a range of organisations including the University of Manchester, the University of Strathclyde, AstraZeneca, Pfizer, Croda, Malvern PANalytical, and Precision Nanosystems. These partners will contribute knowledge and expertise relating to the design, development and manufacture of nanomedicines. The manufacturing platform for this project will exploit microfluidic devices in which the mixing of reagents can be exquisitely controlled. This will deliver structures that allow the development of nanoformulated medicines with highly controlled properties. Use of the selected manufacturing platform technology therefore has the potential to deliver better products and processes, whilst reducing the time taken to develop new nanoformulations for use in the clinical development of investigational medicines.

 

 

“We are thrilled to be working with such a strong consortium of collaborators on a project that will have positive impact for a rapidly emerging market,” says Graeme Cruickshank, Director of CPI’s National Formulation Centre. “The development of this microfluidics platform will underpin our capability to enable companies to robustly scale up novel nanoformulations, improving the chances of a positive result in pre-clinical trials. Ultimately this will lead to benefits for large and small companies alike.”

Yvonne Perrie, Professor of Drug Delivery at the University of Strathclyde, says: “Having worked in the field of liposomes and microfluidics for some time now, we are delighted to be part of this project and add in our experience in developing scalable manufacturing processes for liposomes and nanomedicines.”

News Source: CPI

 

 

blog comments powered by Disqus

Contact

  • janet_todd_netpark

    Janet Todd

    NETPark Manager

    +44(0)1740 625 250
    This email address is being protected from spambots. You need JavaScript enabled to view it.

Did You Know?

  • Catapulting technologies to market +

    NETPark is the only science park in the UK with two Catapults: High Value Manufacturing and Satellite Applications
  • Reinnervate in space... +

    Reinnervate’s cell scaffold technology was carried to the International Space Station in April 2015 for bone density experiments
  • The Number 55 +

    NETPark is number 55 on the list of 100 reasons why it’s great up north
  • Kromek, a home-grown plc +

    Kromek, a company at NETPark, started with 2 employees, now employs 60, is a plc and is building the largest radiation sensor network in the United States
  • PolyPhotonix and the Sleep Mask +

    PolyPhotonix has developed a Sleep Mask to treat diabetic retinopathy which will save the NHS £1BN a year
  • The North East workforce +

    Companies developing products from physics-based science employ over 43,000 people in the North East
  • Starring in Stargazing Live +

    Durham University's Centre for Advanced Instrumentation at NETPark built instruments for the South African Large Telescope and the James Webb Space Telescope, both of which "starred" in BBC's Stargazing Live
  • 1

Keep In Touch

NETPark associations